473 related articles for article (PubMed ID: 19743942)
21. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
Wielage RC; Bansal M; Andrews JS; Klein RW; Happich M
Appl Health Econ Health Policy; 2013 Jun; 11(3):219-36. PubMed ID: 23616247
[TBL] [Abstract][Full Text] [Related]
22. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
Hur C; Chan AT; Tramontano AC; Gazelle GS
Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
[TBL] [Abstract][Full Text] [Related]
23. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM
Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan.
Yen ZS; Lai MS; Wang CT; Chen LS; Chen SC; Chen WJ; Hou SM
J Rheumatol; 2004 Sep; 31(9):1797-803. PubMed ID: 15338503
[TBL] [Abstract][Full Text] [Related]
25. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada.
Rahme E; Toubouti Y; Hunsche E
Rheumatology (Oxford); 2006 Jul; 45(7):903-10. PubMed ID: 16461440
[TBL] [Abstract][Full Text] [Related]
26. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S
Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490
[TBL] [Abstract][Full Text] [Related]
27. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
28. Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?
Rahme E; Barkun AN; Toubouti Y; Scalera A; Rochon S; Lelorier J
Arthritis Rheum; 2007 Jun; 57(5):748-55. PubMed ID: 17530673
[TBL] [Abstract][Full Text] [Related]
29. Efficiency of naproxen/esomeprazole in association for osteoarthrosis treatment in Spain.
Capel M; Tornero J; Zamorano JL; Oyagüez I; Casado MÁ; Sánchez-Covisa J; Lanas A
Reumatol Clin; 2014; 10(4):210-7. PubMed ID: 24380809
[TBL] [Abstract][Full Text] [Related]
30. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
Scheiman JM; Hindley CE
Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
[TBL] [Abstract][Full Text] [Related]
31. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G;
Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
[TBL] [Abstract][Full Text] [Related]
32. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS
J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan.
Sakamoto C; Soen S
Digestion; 2011; 83(1-2):108-23. PubMed ID: 21042022
[TBL] [Abstract][Full Text] [Related]
34. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
Tannenbaum H; Bombardier C; Davis P; Russell AS;
J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
[TBL] [Abstract][Full Text] [Related]
35. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
Mallen SR; Essex MN; Zhang R
Curr Med Res Opin; 2011 Jul; 27(7):1359-66. PubMed ID: 21561397
[TBL] [Abstract][Full Text] [Related]
36. The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals.
Hur C; Simon LS; Gazelle GS
Cancer; 2004 Jul; 101(1):189-97. PubMed ID: 15222006
[TBL] [Abstract][Full Text] [Related]
37. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL
Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial.
Kellner HL; Li C; Essex MN
Curr Med Res Opin; 2012 Sep; 28(9):1537-45. PubMed ID: 22852870
[TBL] [Abstract][Full Text] [Related]
39. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
40. The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial.
Brereton N; Winn B; Akehurst R
J Med Econ; 2012; 15(3):465-72. PubMed ID: 22260652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
